Clinical Trial · NCT02539433

Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

Overview

Imaging of neuroendocrine (NETs), such as carcinoids and pheochromocytomas (PHEOs), is suboptimal, limiting curative treatment. The investigators wanted to explore the use of PET and F-DOPA i.v. for the localization of these types of neoplasms. The investigators used a similar protocol as they had used for PET (Positron emission tomography) or FDG (Fludeoxyglucose) imaging in oncologic patients. F-DOPA, prepared according to United States Pharmacopeia (USP) guidelines, was approved by the North Shore University Hospital Radiation Safety Committee in 1989 and 1994 for the study of neurological diseases and used uneventfully.

Sponsor

Unknown Organization

Phase

N/A

Contacts

Josephine Rini, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02539433

Drug / Compound

DOPA

Isotope(s):

Target(s):

Amino Acid Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Appropriate diagnosis by referring physician

Exclusion

Prior history of radiation treatment
Pregnancy
Chemotherapy or anti-tuberculosis medications.
Lactation